logo.png
Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
June 11, 2021 01:03 ET | F. Hoffmann-La Roche Ltd
Four-year follow-up analysis from the phase III CLL14 study showed progression-free survival rate of 74.0% in previously untreated patients with chronic lymphocytic leukaemia (CLL) three years after...
logo.png
New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA)
June 11, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Data from JEWELFISH, the first trial in a diverse population aged 1 to 60 years with SMA who received prior treatment, showed a consistent safety profile and >2-fold increase in SMN protein...
logo.png
Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at home
June 08, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
The SARS-CoV-2 Antigen Self Test Nasal enables individuals to quickly and conveniently test themselves for COVID-19 at home using a simple nasal swab An early version of the test has already been...
logo.png
Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma
June 04, 2021 08:00 ET | F. Hoffmann-La Roche Ltd
Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin lymphoma in early studies Basel, 4 June...
logo.png
European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
May 25, 2021 08:00 ET | F. Hoffmann-La Roche Ltd
With hypomethylating agents significantly improved complete response rates in certain adults with newly diagnosed acute myeloid leukaemiaIn the VIALE-A study, Venclyxto plus azacitidine significantly...
logo.png
Pivotal Phase III data at ASCO show Roche’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning
May 20, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Tecentriq improved disease-free survival by more than one-third in people with PD-L1-positive resectable early-stage lung cancer, compared with best supportive careFirst and only cancer immunotherapy...
logo.png
Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
May 11, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Data from the first positive phase III study of a cancer immunotherapy in early, resected lung cancerStudies in personalised healthcare exploring tumour agnostic treatments that demonstrate the impact...
logo.png
Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
May 05, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III studyTecentriq approval offers an alternative to chemotherapy for all...
logo.png
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for previously untreated metastatic bladder cancer
April 28, 2021 16:00 ET | F. Hoffmann-La Roche Ltd
Basel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining...
logo.png
Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
April 28, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Cardiovascular diseases are responsible for 17.9 million deaths every year¹, a third of all deaths globally²Roche announces five new intended uses for key cardiac biomarkers to help identify...